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Abstract
Background: The 1100delC CHEK2 allele has been associated with a 1.4–4.7 fold increased risk
for breast cancer in women carrying this mutation. While the frequency of 1100delC was 1.1–1.4%
in healthy Finnish controls, the frequency of this allele in a North American control population and
in North American breast cancer kindreds remains unclear.
Methods: We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for
the CHEK2*1100delC.
Results: The overall frequency of the 1100delC was 3/300 (1.0%) among all cases with either a
family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which
46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency
of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among
Ashkenazi and non-Ashkenazi controls.
Conclusion: The relatively low breast cancer penetrance of this allele, along with the low
population frequency, will limit the clinical applicability of germline testing for CHEK2*1100delC in
North American kindreds.
Background
In response to DNA damage, the cell-cycle checkpoint ki-
nase CHEK2 can be activated by ATM kinase to phospho-
rylate p53 and BRCA1, which are involved in cell-cycle
control, apoptosis, and DNA repair [1,2]. A germline mu-
tation 1100delC truncates the CHEK2 protein and was first
observed in families exhibiting Li-Fraumeni syndrome
[3]. To address the possibility that this allele contributes
to increased susceptibility to breast cancer, two recent
studies have investigated the frequency of
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et al. [4] reported that the 1100delC protein-truncating
mutation of CHEK2 was observed in 5.5% of 507 patients
with a family history of breast cancer and no detectable
BRCA mutation compared to 1.4% of 1,885 healthy Finn-
ish controls. The CHEK2-Breast Cancer Consortium ob-
served a 5.1% frequency of this allele in 1071 individuals
with breast cancer derived from multiple-case families in
which no mutations in BRCA1 or BRCA2 were detected,
compared to a 1.1% of 1,620 healthy (mostly Northern
European) controls [5]. These two groups also reported an
increased frequency of CHEK2*1100delC in kindreds with
male breast cancer or bilateral breast cancer. We report
here the frequency of CHEK2*1100delC in North Ameri-
can breast cancer patients and controls.
Methods
We have analyzed a North American sample of healthy
controls participating in the New York Cancer Project, and
two series of cases: those enrolled in a genetic counseling
clinic as well as a separate series of cases unselected for
family history ascertained at Memorial Sloan-Kettering
Cancer Center. The cases and controls self-identified
themselves as Jewish or non-Jewish and reported their an-
cestor's countries of origin. The population control sam-
ples were derived from the New York Cancer Project, an
ongoing cohort study enrolling healthy volunteers. Of the
569 non-Ashkenazi controls participating in this study, 62
were African-American, 37 Hispanic, 20 Asian, 18 Other/
Unknown, and 432 Caucasian. All individuals in this
study provided informed consent for future DNA analysis.
Genomic DNA was extracted and amplified utilizing
CHEK2 external PCR primers:
9Fe 5' CTGTCATCTCAAGAAGAGGACT and
10R 5' ATTTGTGACTTCATCTAATCACCTCC
and internal PCR primers:
9F 5' TGGCAAGTTCAACATTATTCCC and
10Re 5' GAATAACTCCTAAACTCCAGC
Genotyping was performed by dHPLC (Transgenomics,
USA) or Pyrosequencing (Pyrosequencing, Inc. Sweden);
all mutations were confirmed by both of these methodol-
ogies. Non-Ashkenazi individuals were screened by DNA
sequencing for mutations in the entire BRCA1 and BRCA2
coding sequence and Ashkenazi individuals were screened
for the three founder alleles that account for >95% of mu-
tations in this ethnic group [6].
Results
We observed CHEK2*1100delC in 5/1665 (0.3%) of
healthy New York City controls, significantly lower than
the frequency in controls reported by Vahteristo et al. (p =
0.0004, Fisher's Exact test) or by the CHEK2 Consortium
(p = 0.006). Within our sample, 3/1096 (0.3%) individu-
als of Jewish (predominantly Ashkenazi) descent carried
this allele, a rate comparable to the 0.4% frequency (2/
569) observed in individuals of non-Ashkenazi descent.
We detected CHEK2*1100delC in 1/100 index cases from
multiple-case breast cancer families in which mutations in
BRCA1 or BRCA2 were not detected. As noted in Table 1,
the one case heterozygous for the 1100delC was an indi-
vidual of Ashkenazi descent seen at our Center who was
previously included in the report by the CHEK2-Breast
Cancer Consortium. Of these 100 families, 33 were of
Ashkenazi descent and 67 were of non-Ashkenazi origin.
CHEK2*1100delC was detected in 0/16 male individuals
with breast cancer without mutations in BRCA2, and in 1/
46 (2.2%) of clinic-ascertained bilateral breast cancer cas-
es in individuals with a family history of breast cancer
who were also of Ashkenazi Jewish descent compared to
0/46 clinic-ascertained unilateral breast cancer cases
matched by age, ethnicity and family history. In a separate
series of bilateral breast cancer cases unselected for family
history, 0/46 carried CHEK2*1100delC, compared to 1/46
unilateral breast cancer cases matched to the bilateral cas-
es by age and ethnicity. Taking all of the breast cancer cas-
es combined, the frequency of the 1100delC was 3/300
(1.0%) compared to the population frequency of 5/1665
(0.3%) (p = 0.10).
Discussion
Our current findings do not exclude the possibility that
the CHEK2*1100delC variant increases the relative risk for
breast cancer in North Americans. Because this variant oc-
curs significantly less commonly in healthy New York
controls compared to Northern European controls, the
low frequency of this allele in multiple-case families, bi-
lateral cases, and male breast cancer cases could still be
compatible with a relative risk in the range of 3.5–12 as re-
ported by Vahteristo et al. and the CHEK2-Breast Cancer
Consortium.
A prior attempt to analyze the entire CHEK2 gene in a
northern European cohort was unable to detect mutations
in exons 10–14, including the 1100delC, in 79 BRCA1/2-
negative individuals from Finnish families with three or
more cases of breast cancer [7]. The relative size of the
population control samples in our studies was compara-
ble to prior studies (1,620 population controls in the
CHEK2-Consortium, 1,885 in Vahteristo et al, and 1,665
in the current study). We evaluated 100 BRCA mutation-
negative breast cancer families, compared to 216 in the re-
port by Vahteristo et al, and 718 in the Consortium study.Page 2 of 4
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by Begg et al [8], of an "enrichment" of germline carriers
of cancer predisposition alleles in individuals with bilat-
eral breast cancer. Our series analyzed 92 cases of bilateral
breast cancer and 92 controls, compared to 33 bilateral
breast cancer cases included in the report by Vahteristo et
al. While no enrichment was noted in our bilateral cases
compared to unilateral cases, this may also reflect the low-
er population frequency of the allele in our population.
Further study of the frequency of the CHEK2*1100delC al-
lele in North American breast cancer kindreds is warrant-
ed, however, the relative rarity of this allele in our
population, plus the relatively low breast cancer pene-
trance reported for this allele, limit the clinical relevance
in North American kindreds of CHEK2*1100delC as a can-
cer-predisposing allele.
Conclusions
The 0.3% frequency of the 1100delC CHEK2 allele in a
New York population is significantly lower than the 1.1–
1.4% rate observed in Northern European populations.
This allele was infrequent in BRCA1/2 wild-type cases
with family history of breast cancer or in cases with a per-
sonal history of unilateral or bilateral of breast cancer. The
relatively low breast cancer penetrance, along with the low
population frequency, limit the clinical relevance in





KO designed the study and wrote the final draft of the pa-
per; HP helped in the design and coordinated specimen
collection; TK, KN, and PK performed genotype analysis
and wre supervised by NE who also participated in study
design; BR wrote the first draft of the manuscript and co-
ordinated data collection; PK and SG oversaw collection
of control samples and participated in study design; OY
ascertained the familial breast cases and helped with study
design; HH helped with data collection and analysis, JS
provided biostatistical analysis; MR and LS participated in
study design and analysis.
Acknowledgments
The authors would like to acknowledge the New York Cancer Project, 
which in connection with the publication of this study made available bio-
logical samples from and information on control individuals. The New York 
Cancer Project is administered and funded by AMDeC Foundation, Inc. We 
also acknowledge support of the Koodish Fellowship, the Frankel Founda-
tion, the Lymphoma Foundation and the Danziger Foundation.
References
1. Chehab NH, Malikzay A, Appel M and Halazonetis TD Chk2/hCds1
functions as a DNA damage checkpoint in G(1) by stabilizing
p53. Genes Dev 2000, 14:278-288
2. Lee JS, Collins KM, Brown AL, Lee CH and Chung JH hCds1-medi-
ated phosphorylation of BRCA1 regulates the DNA damage
response. Nature 2000, 404:201-204
3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC and Shannon
KE Heterozygous germ line hCHK2 mutations in Li-Fraume-
ni syndrome. Science 1999, 286:2528-2523
4. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S and Kilpivaara
O CHEK2 Genetic Variant Contributing to a Substantial
Fraction of Familial Breast Cancer. Am J Hum Genet 2002,
71:432-438
5.  The CHEK2 Breast Cancer Consortium Low-penetrance suscep-
tibility to breast cancer due to CHEK2*1100delC in noncarri-
ers of BRCA1 or BRCA2 mutations. Nature Genet 2002, 31:55-59
6. Kauff N, Perez-Segura P, Robson M, Scheuer L, Siegel B and Schluger
A Incidence of non-founder BRCA1 and BRCA2 mutations in
high-risk Ashkenazi breast and ovarian cancer families. J Med-
ical Genet 2002, 39:611-614
7. Allinen M, Huusko P, Mantyniemi S, Launonen V and Winqvist R Mu-
tation analysis of the CHK2 gene in families with hereditary
breast cancer. Br J Cancer 2001, 85:209-212
Table 1: CHEK2*1100delC in breast cancer cases and healthy controls
Positive for CHEK2*1100delC (%)
Controls
Jewish (New York) 3/1096 (0.3%)
Non-Jewish (New York) 2/569 (0.4%)
Total 5/1665 (0.3%)
BRCA1/2-negative individuals of mixed ethnicity with breast cancer from families with 3 or more cases of breast 
cancer
0/67 (0.0%)
BRCA1/2 Ashkenazi founder mutation-negative individuals with breast cancer from families with 3 or more 
cases of breast cancer
1/33# (3.0%)
BRCA2-negativei individuals of mixed ethnicity with male breast cancer 0/16 (0.0%)
Individuals with bilateral breast cancer of mixed ethnicity unselected for family history 0/46 (0.0%)
Individuals with unilateral breast cancer unselected for family history matched for age, ethnicity 1/46 (2.2%)
Clinic-ascertained individuals of Ashkenazi Jewish descent with bilateral breast cancer 1/46 (2.2%)
Clinic-ascertained individuals of Ashkenazi Jewish descent with unilateral breast cancer matched for age, family 
history
0/46 (0.0%)
#This case previously reported in CHEK2 Breast Cancer Consortium [5].Page 3 of 4
(page number not for citation purposes)
BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/1Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
8. Begg CB and Berwick M A note on the estimation of relative
risks of rare genetic susceptibility markers. Cancer Epidemiol Bi-
omarkers Prev 1997, 6:99-103
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/4/1/prepubPage 4 of 4
(page number not for citation purposes)
